SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
Yongheng Liu(Kelun Group (China)), Jingyi Wang(Qingdao University), Qing Yan(Kelun Group (China)), Xi Zhao(Chongqing Medical University), Wei Lian(Kelun Group (China)), Tongtong Xue(Beijing Institute of Technology), Xiao Liang(Harbin Medical University), Yina Diao(Kelun Group (China)), Jian Xu(University of California, Los Angeles)
Cited by 21
Related Papers
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription
|Nature Communications|2019|254
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
|Pharmacology & Therapeutics|2019|245